FR21C1051I2 - NEW HYDROGENOSULFATE SALT - Google Patents

NEW HYDROGENOSULFATE SALT

Info

Publication number
FR21C1051I2
FR21C1051I2 FR21C1051C FR21C1051C FR21C1051I2 FR 21C1051 I2 FR21C1051 I2 FR 21C1051I2 FR 21C1051 C FR21C1051 C FR 21C1051C FR 21C1051 C FR21C1051 C FR 21C1051C FR 21C1051 I2 FR21C1051 I2 FR 21C1051I2
Authority
FR
France
Prior art keywords
hydrogenosulfate
salt
new
new hydrogenosulfate
hydrogenosulfate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1051C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Array Biopharma Inc
Original Assignee
AstraZeneca AB
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218759&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1051(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB, Array Biopharma Inc filed Critical AstraZeneca AB
Publication of FR21C1051I1 publication Critical patent/FR21C1051I1/en
Application granted granted Critical
Publication of FR21C1051I2 publication Critical patent/FR21C1051I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
FR21C1051C 2005-12-21 2021-11-05 NEW HYDROGENOSULFATE SALT Active FR21C1051I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75278105P 2005-12-21 2005-12-21
PCT/US2006/061895 WO2007076245A2 (en) 2005-12-21 2006-12-12 Novel hydrogen sulfate salt

Publications (2)

Publication Number Publication Date
FR21C1051I1 FR21C1051I1 (en) 2021-12-24
FR21C1051I2 true FR21C1051I2 (en) 2023-02-17

Family

ID=38218759

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1051C Active FR21C1051I2 (en) 2005-12-21 2021-11-05 NEW HYDROGENOSULFATE SALT

Country Status (31)

Country Link
US (4) US20100016393A1 (en)
EP (1) EP1968948B1 (en)
JP (1) JP5127723B2 (en)
KR (1) KR101361460B1 (en)
CN (2) CN101360718B (en)
AR (1) AR058696A1 (en)
AU (1) AU2006330759B2 (en)
BR (1) BRPI0620091A2 (en)
CA (1) CA2634149C (en)
CY (1) CY1114303T1 (en)
DK (1) DK1968948T3 (en)
EC (1) ECSP088597A (en)
ES (1) ES2421746T3 (en)
FR (1) FR21C1051I2 (en)
HK (1) HK1124043A1 (en)
HR (1) HRP20130663T1 (en)
HU (1) HUS2100046I1 (en)
IL (1) IL192224A (en)
LT (1) LTC1968948I2 (en)
MX (1) MX2008008298A (en)
MY (1) MY157733A (en)
NL (1) NL301139I2 (en)
NZ (1) NZ569792A (en)
PL (1) PL1968948T3 (en)
PT (1) PT1968948E (en)
RS (1) RS52843B (en)
SI (1) SI1968948T1 (en)
TW (1) TWI405756B (en)
UA (1) UA93531C2 (en)
WO (1) WO2007076245A2 (en)
ZA (1) ZA200805705B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulfate salt
US20100004247A1 (en) * 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
LT3702351T (en) 2012-10-19 2024-01-10 Array Biopharma, Inc. Formulation comprising a mek inhibitor
BR112015020787B1 (en) 2013-03-06 2022-12-06 Astrazeneca Ab 4-(SUBSTITUTED-ANILINE)-6-O-(SUBSTITUTED-PIPERIZINE-CARBONYL)QUINAZOLINIC COMPOUNDS, THEIR SALTS, PHARMACEUTICAL COMPOSITION, USE AND COMBINATION
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN105566327A (en) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 JAK kinase inhibitor bisulfate crystal type I and preparation method thereof
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
MX2018004309A (en) * 2015-10-06 2018-05-22 Redhill Biopharma Ltd Combination therapies for treating cancer.
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
CN109438362B (en) * 2017-11-14 2020-07-21 深圳市塔吉瑞生物医药有限公司 Substituted benzimidazole compound and composition containing same
CR20210211A (en) * 2018-10-31 2021-05-25 Vernalis R&D Ltd Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
US20220405506A1 (en) * 2021-06-22 2022-12-22 Intrinsic Innovation Llc Systems and methods for a vision guided end effector
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (en) 1997-02-03 2000-02-21 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives.
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SG148857A1 (en) * 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
MXPA06002657A (en) 2003-09-09 2006-06-05 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma.
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulfate salt
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition

Also Published As

Publication number Publication date
HK1124043A1 (en) 2009-07-03
US9156795B2 (en) 2015-10-13
ECSP088597A (en) 2008-08-29
SI1968948T1 (en) 2013-08-30
US20120253049A1 (en) 2012-10-04
RS52843B (en) 2013-12-31
MY157733A (en) 2016-07-15
FR21C1051I1 (en) 2021-12-24
LTPA2021530I1 (en) 2021-12-27
NL301139I2 (en) 2022-02-22
JP2009521487A (en) 2009-06-04
CN101360718A (en) 2009-02-04
CA2634149C (en) 2013-08-13
DK1968948T3 (en) 2013-08-26
ES2421746T3 (en) 2013-09-05
NZ569792A (en) 2011-01-28
US20160024018A1 (en) 2016-01-28
NL301139I1 (en) 2021-11-03
CA2634149A1 (en) 2007-07-05
TW200800915A (en) 2008-01-01
ZA200805705B (en) 2012-09-26
EP1968948A4 (en) 2010-12-15
JP5127723B2 (en) 2013-01-23
WO2007076245A3 (en) 2008-01-24
CN101360718B (en) 2012-01-11
AU2006330759B2 (en) 2012-12-06
EP1968948A2 (en) 2008-09-17
EP1968948B1 (en) 2013-05-22
KR101361460B1 (en) 2014-02-10
PL1968948T3 (en) 2013-10-31
HRP20130663T1 (en) 2013-08-31
AR058696A1 (en) 2008-02-20
AU2006330759A1 (en) 2007-07-05
MX2008008298A (en) 2008-09-24
WO2007076245A2 (en) 2007-07-05
KR20080080200A (en) 2008-09-02
UA93531C2 (en) 2011-02-25
IL192224A (en) 2014-08-31
LTC1968948I2 (en) 2023-07-10
IL192224A0 (en) 2009-02-11
HUS2100046I1 (en) 2021-11-29
CN102329270A (en) 2012-01-25
CY1114303T1 (en) 2016-08-31
US20100016393A1 (en) 2010-01-21
PT1968948E (en) 2013-07-25
US20140221443A1 (en) 2014-08-07
BRPI0620091A2 (en) 2011-11-01
TWI405756B (en) 2013-08-21
US9562017B2 (en) 2017-02-07

Similar Documents

Publication Publication Date Title
FR21C1051I2 (en) NEW HYDROGENOSULFATE SALT
NO2021013I1 (en) filgotinib or a salt thereof
LTC2343304I2 (en) BIOCIDAL BORONOPHTHALIDE COMPOUNDS
NL300885I2 (en) Irinotecansucrophosphate salt
ATE458725T1 (en) PIPERAZINE COMPOUNDS WITH HERBICIDAL EFFECT
ATE463485T1 (en) PIPERAZINE COMPOUNDS WITH HERBICIDAL EFFECT
BRPI0816278A2 (en) salt form
ATE449085T1 (en) PIPERAZINE COMPOUNDS WITH HERBICIDAL EFFECT
ATE502948T1 (en) SUBSTITUTED BICYCLOLACTAM COMPOUNDS
DK1919907T3 (en) Heterocyclic compound
EP2305641A4 (en) Sulfonamide compound or salt thereof
DK1937650T3 (en) Heterocyclic Compounds
ATE443056T1 (en) SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXYACETAMIDE COMPOUNDS
BRPI0807004A2 (en) SALT
UY3776Q (en) WRISTWATCH
DE602008000563D1 (en) fishing reel
DE602008006282D1 (en) fishing reel
ZA200800522B (en) New salt II
ATE518827T1 (en) ALISKIREN NITRATE SALT
SE530154C8 (en) salt mixture
FI7694U1 (en) Lure
NO346433B1 (en) New fish pathogen
ATE474459T1 (en) FISHING ROD
FR2885162B1 (en) NEW TYPE OF SHUTTER.
ZA200800488B (en) New Salt III